Prevention of Fungal Disease

  • Shirish HuprikarEmail author
  • John R. Wingard


Invasive fungal infections are an important problem in the management of both solid organ and hematopoietic stem cell transplant recipients. This chapter summarizes the evidence and recommendations for preventing invasive fungal infections in transplant recipients. A summary of recommendations are presented in Table 64.1.


Liver transplant Kidney transplant Hematopoietic stem cell transplant Aspergillosis Invasive candidiasis 


  1. 1.
    Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Silveira FP, Kusne S, ASTIDCo P. Candida infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):220–7.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Singh N, Husain S, ASTIDCo P. Aspergillosis in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):228–41.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant. 2008;8(2):426–31.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Saliba F, Delvart V, Ichai P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. Clin Transpl. 2013;27(4):E454–61.CrossRefGoogle Scholar
  7. 7.
    Braun F, Ruchel R, Lorf T, et al. Is liposomal amphotericin B (ambisome) an effective prophylaxis of mycotic infections after liver transplantation? Transplant Proc. 1998;30(4):1481–3.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Lorf T, Braun F, Ruchel R, Muller A, Sattler B, Ringe B. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses. 1999;42(1–2):47–53.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation. 1995;59(1):45–50.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(10):729–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis. 1996;174(3):583–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David Colby W. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation. 2003;76(6):977–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation. 2002;74(5):688–95.PubMedCrossRefGoogle Scholar
  14. 14.
    Biancofiore G, Bindi ML, Baldassarri R, et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl Int. 2002;15(7):341–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Mora NP, Klintmalm G, Solomon H, Goldstein RM, Gonwa TA, Husberg BS. Selective amphotericin B prophylaxis in the reduction of fungal infections after liver transplant. Transplant Proc. 1992;24(1):154–5.PubMedGoogle Scholar
  16. 16.
    Kung N, Fisher N, Gunson B, Hastings M, Mutimer D. Fluconazole prophylaxis for high-risk liver transplant recipients. Lancet. 1995;345(8959):1234–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Decruyenaere J, Colardyn F, Vogelaers D, et al. Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Transplant Proc. 1995;27(6):3515–6.PubMedGoogle Scholar
  18. 18.
    Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transplant. 2005;11(6):656–62.CrossRefGoogle Scholar
  19. 19.
    Singhal S, Ellis RW, Jones SG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transplant. 2000;6(5):588–95.CrossRefGoogle Scholar
  20. 20.
    Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation. 2001;71(7):910–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother. 2003;52(5):813–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Shah T, Lai WK, Gow P, Leeming J, Mutimer D. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis. 2005;7(3–4):126–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Castroagudin JF, Ponton C, Bustamante M, et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc. 2005;37(9):3965–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Hadley S, Huckabee C, Pappas PG, et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis. 2009;11(1):40–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87(3):424–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14(12):2758–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant. 2006;6(2):386–91.PubMedCrossRefGoogle Scholar
  28. 28.
    San-Juan R, Aguado JM, Lumbreras C, et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation. 2011;92(3):346–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transplant. 2006;12(5):850–8.CrossRefGoogle Scholar
  30. 30.
    Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 2006;25(9):549–61.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Bhaskaran A, Mumtaz K, Husain S. Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep. 2013;15(6):514–25.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant. 2004;23(12):1376–81.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis. 2006;8(4):213–8.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation--a world-wide survey. Am J Transplant. 2011;11(2):361–6.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc. 1997;29(1–2):627–8.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant. 2001;20(12):1274–81.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Monforte V, Ussetti P, Lopez R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28(2):170–5.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Monforte V, Ussetti P, Gavalda J, et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant. 2010;29(5):523–30.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Borro JM, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. 2008;40(9):3090–3.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Husain S, Capitano B, Corcoran T, et al. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation. 2010;90(11):1215–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant. 2006;6(11):2765–73.PubMedCrossRefGoogle Scholar
  42. 42.
    Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72(3):545–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation. 2004;77(2):232–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Lowry CM, Marty FM, Vargas SO, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis. 2007;9(2):121–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest. 1999;115(5):1301–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis. 2002;4(4):195–200.PubMedCrossRefGoogle Scholar
  47. 47.
    Mattner F, Chaberny IF, Weissbrodt H, et al. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole. Mycoses. 2005;48(Suppl 1):51–5.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant. 2005;24(12):2148–52.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6(12):3008–16.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant. 2009;9(9):2085–91.PubMedCrossRefGoogle Scholar
  51. 51.
    Kramer MR, Amital A, Fuks L, Shitrit D. Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. Clin Transpl. 2011;25(2):E163–7.CrossRefGoogle Scholar
  52. 52.
    Berenguer J, Munoz P, Parras F, Fernandez-Baca V, Hernandez-Sampelayo T, Bouza E. Treatment of deep mycoses with liposomal amphotericin B. Eur J Clin Microbiol Infect Dis. 1994;13(6):504–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004;4(4):636–43.PubMedCrossRefGoogle Scholar
  54. 54.
    Munoz P, Alcala L, Sanchez Conde M, et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation. 2003;75(3):326–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Paniagua Martin MJ, Marzoa Rivas R, Barge Caballero E, et al. Efficacy and tolerance of different types of prophylaxis for prevention of early aspergillosis after heart transplantation. Transplant Proc. 2010;42(8):3014–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Munoz P, Valerio M, Palomo J, et al. Targeted antifungal prophylaxis in heart transplant recipients. Transplantation. 2013;96(7):664–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Benedetti E, Gruessner AC, Troppmann C, et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg. 1996;183(4):307–16.PubMedGoogle Scholar
  58. 58.
    Humar A, Kandaswamy R, Granger D, Gruessner RW, Gruessner AC, Sutherland DE. Decreased surgical risks of pancreas transplantation in the modern era. Ann Surg. 2000;231(2):269–75.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.PubMedCrossRefGoogle Scholar
  60. 60.
    Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.PubMedCrossRefGoogle Scholar
  61. 61.
    Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96(6):2055–61.PubMedGoogle Scholar
  62. 62.
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med. 2002;112(5):369–79.PubMedCrossRefGoogle Scholar
  64. 64.
    Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909–17.PubMedCrossRefGoogle Scholar
  65. 65.
    van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16.PubMedCrossRefGoogle Scholar
  66. 66.
    Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.PubMedCrossRefGoogle Scholar
  68. 68.
    Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.PubMedCrossRefGoogle Scholar
  70. 70.
    Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–27.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950–2.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39(4):584–7.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–60.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116(2):475–82.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant. 2004;33(9):943–8.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28(2):331–40.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Proia L, Miller R. Endemic fungal infections in solid organ transplant recipients. Am J Transplant. 2009;9. Suppl 4:S199–207.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001;33(9):1536–44.PubMedCrossRefGoogle Scholar
  81. 81.
    Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis. 2003;5(1):3–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Braddy CM, Heilman RL, Blair JE. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant. 2006;6(2):340–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Blair JE, Kusne S, Carey EJ, Heilman RL. The prevention of recrudescent coccidioidomycosis after solid organ transplantation. Transplantation. 2007;83(9):1182–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Keckich DW, Blair JE, Vikram HR, Seville MT, Kusne S. Reactivation of coccidioidomycosis despite antifungal prophylaxis in solid organ transplant recipients. Transplantation. 2011;92(1):88–93.PubMedCrossRefGoogle Scholar
  85. 85.
    Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant. 2011;11(1):111–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Vikram HR, Dosanjh A, Blair JE. Coccidioidomycosis and lung transplantation. Transplantation. 2011;92(7):717–21.PubMedCrossRefGoogle Scholar
  87. 87.
    Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis. 2002;4(3):148–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.The Mount Sinai HospitalIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.University of Florida, Division of Hematology/OncologyDepartment of MedicineGainesvilleUSA

Personalised recommendations